. Ilya-khantalin, . Md-stéphane-ramin-mangata, . Bs-kévin-chemello, P. Bs-brice-nativel, . J. Dirk et al.,

S. Clotilde, France E-mail: gilles.lambert@univ-reunion

, The authors have reported that they have no relationships relevant to the contents of this paper to disclose. Mr. Blanchard and Dr, This work was funded by the program grant CHOPIN (CHolesterol Personalized Innovation) granted by the Agence Nationale de la Recherche

P. M. Moriarty, S. A. Varvel, P. L. Gordts, J. P. Mcconnell, and S. Tsimikas, Lipoprotein(a) mass levels increase significantly according to APOE genotype: an analysis of 431 239 patients, Arterioscler Thromb Vasc Biol, vol.37, pp.580-588, 2017.

R. Alonso, E. Andres, and N. Mata, Lipoprotein(a) levels in familial hipercholesterolemia: an important predictor for cardiovascular disease independent of the type of LDL-receptor mutation, J Am Coll Cardiol, vol.63, pp.1982-1991, 2014.

P. Willeit, P. M. Ridker, and P. J. Nestel, Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials, Lancet, vol.392, pp.1311-1331, 2018.

V. Blanchard, S. Ramin-mangata, and S. Billon-crossouard, Kinetics of plasma apolipoprotein E isoforms by LC-MS/MS: a pilot study, J Lipid Res, vol.59, pp.892-900, 2018.
URL : https://hal.archives-ouvertes.fr/hal-01833926

G. Lambert, F. Petrides, and M. Chatelais, Elevated plasma PCSK9 level is equally detrimental for patients with nonfamilial hypercholesterolemia and heterozygous familial hypercholesterolemia, irrespective of low-density lipoprotein receptor defects, J Am Coll Cardiol, vol.63, pp.2365-73, 2014.